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Objective: Assess whether CD70+ B cells contribute to EAE.
Materials and methods: MOG-speciﬁc TCR transgenic mice (2D2) were crossed with mice with constitutive
CD70 expression on B cells. The development of EAE and the phenotype of B-T lymphocytes were studied
in 2D2xCD70 animals.
Results: Spontaneous EAE developed in 20% of 2D2xCD70 and 3% of 2D2 mice. EAE was also more severe in
2D2xCD70 versus 2D2 animals upon MOG immunization. The susceptibility of 2D2xCD70 to EAE was associ-
ated with fewer FoxP3+ T cells.
Conclusions: Expression of CD70 by B cells aggravates EAE possibly by reducing the number of regulatory T
cells. © 2012 Elsevier B.V. Open access under the Elsevier OA license.1. Introduction
B lymphocytes play important pathogenic roles in a wide variety of
autoimmune diseases, as demonstrated by the association of
autoimmune diseases with single nucleotide polymorphisms (SNPs)
in molecules related to BCR signaling (Harley et al., 2008; Kozyrev et
al., 2008; Arechiga et al., 2009; Habib et al., 2012), defects in B cell
central tolerance check points (Yurasov et al., 2005; Menard et al.,
2011), the presence of disease-speciﬁc autoantibodies (LaGasse et al.,
2002; Arbuckle et al., 2003; Nielen et al., 2004), and the clinical efﬁcacy
of B cell directed therapies in diseases such as rheumatoid arthritis
(Edwards et al., 2004; Dorner et al., 2010), type 1 diabetes (Pescovitz
et al., 2009) and systemic lupus erythematosus (Looney et al., 2004;
van Vollenhoven et al., 2004; Gunnarsson et al., 2007; Camous et al.,
2008). B cells also play a pivotal role in autoimmune diseases that are
considered driven by pathogenic T cells, with as prototypical example
multiple sclerosis (MS). MS does not display the genetic risk factors
for B cell autoimmunity such as PTPN22 SNPs and myelin-directed
autoantibodies are not thought to be fully pathogenic (Schluesener et
al., 1987; Linington et al., 1988; Genain et al., 1995). However, B celleumatology, F4-114, Academic
f 9, 1105 AZ Amsterdam, The
58.
.
vier OA license. depletion does have a beneﬁcial effect in this T cell mediated disorder
(Hauser et al., 2008). These ﬁndings in patients are paralleled by studies
in myelin oligodendrocytic glycoprotein (MOG)-induced experimental
autoimmune encephalomyelitis (EAE). This experimental MS model is
heavily dependent on B cells (Gausas et al., 1982; Lyons et al., 1999),
even though knock-in of an MOG-reactive IgH gene does not result in
pathology despite increased autoantibody titers (Litzenburger et al.,
1998). Using MOG-speciﬁc TCR transgenic animals (Bettelli et al.,
2003), we demonstrated that MOG-speciﬁc B cells contribute to
pathology by capturing, processing and presenting autoantigen to
autoreactive T cells, hence triggering pathogenic T cell autoimmunity
rather than by increasing autoantibody titers (Bettelli et al., 2006;
Krishnamoorthy et al., 2006).
Besides TCR triggering by the MHC-antigen complex, T cell activa-
tion requires adequate costimulation by antigen presenting cells
(APC) through molecular complexes such as CD40-CD40L (Grewal
and Flavell, 1996; Elgueta et al., 2009), CD80/86-CD28 (Slavik et al.,
1999; Carreno and Collins, 2002), ICOS-ICOSL (Shilling et al., 2006;
Simpson et al., 2010), and CD70-CD27 (Nolte et al., 2009; Denoeud
and Moser, 2011). Most costimulatory molecules are not constitutive-
ly expressed on APCs but upregulated upon activation. Upregulation
of costimulatory molecules is not only required for appropriate
protective immune responses but also plays an important role in
autoimmune disease, as they may contribute to the break tolerance.
The role of the CD28-B7.1/B7.2 costimulation pathway in driving
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Salomon et al., 2001). Interference with these signals leads to signiﬁ-
cant protection in many experimental autoimmune models (Nurieva
et al., 2009), and abrogation of B7.1/B7.2 costimulation by CTLA4-Ig
treatment is a highly effective treatment for human RA (Kremer et
al., 2003).
The CD27-CD70pathway is also very important in costimulation of T
cells (Watts, 2005). A few studies report that its blockade is beneﬁcial in
EAE and colitis (Nakajima et al., 2000; Manocha et al., 2009). Nonethe-
less, its contribution to autoimmunity is less well understood and no
therapeutic exploitation of thesemolecules in human autoimmune dis-
orders has been reported yet. The role of B cells as APCs in T
cell-mediated autoimmune diseases and the fact that costimulation
can lower the activation threshold of T lymphocytes (van Gisbergen et
al., 2011), raise the question whether altered expression of
costimulatory molecules on B cells would promote the activation of
self-reactive T cells, triggering the progression from autoimmunity to
overt autoimmune disease. To address this question, we crossed
MOG-speciﬁc TCR transgenic mouse (2D2 mice) in which 5% of the an-
imals develop spontaneous EAE (Bettelli et al., 2003), with mice consti-
tutively expressing CD70 on B lymphocytes (Arens et al., 2001). We
previously reported that B cell speciﬁc CD70 overexpression on a wild
type TCR background induces strong activation and IFNγ production
by effector T cells, (Arens et al., 2001). In this study, we hypothesized
that CD70 overexpression on B cells would have a similar effect on the
MOG-speciﬁc autoreactive T cells, which in this model can be tracked
as they express the TCR β-chain family β11 (vβ11) (Bettelli et al.,
2003), thus leading to a higher incidence and/or severity of EAE. If
strong costimulation could cause overt autoimmune disease by modu-
lating either the amplitude or the quality of the pathogenic and/or reg-
ulatory T cell response, the CD27-CD70 pathway could become a good
therapeutic target in MS. Our results supported our hypothesis and
showed that CD70 costimulation indeed triggered overt EAE, neverthe-
less, no changes were observed in the T cell effector compartment but
rather in the regulatory T cell subset.
2. Materials and methods
2.1. Ethics statement
All animal experiments were performed according to The Nether-
lands local regulations and approved by the Animal Ethics Committee
of the Academic Medical Center/University of Amsterdam.
2.2. Animals
2D2 transgenic C57BL/6J mice were provided by Dr. V. Kuchroo
(Harvard Medical School, Boston, MA) (Bettelli et al., 2003). CD70
F12 transgenic animals (Arens et al., 2001) were housed under SPF
conditions in the animal facility of the Academic Medical Center/
University of Amsterdam (Amsterdam, The Netherlands). 2D2 mice
were crossed with CD70 mice and the F1 generation of 2D2 and
2D2xCD70 littermates was used for EAE experiments.
2.3. Experimental autoimmune encephalomyelitis
Non-immunized mice (32 control 2D2 mice and 44 2D2xCD70
littermates) were observed for 20 weeks for the development of spon-
taneous EAE. In a second set of experiments, EAEwas induced by subcu-
taneous immunization of 7–8 week old mice (16 control 2D2 animals
and 18 2D2xCD70 littermates) with 13 μg of recombinant rat myelin-
oligodendrocyte glycoprotein (MOG) (amino acid residues 1–125)
(AnaSpec, Freemont CA) emulsiﬁed in complete Freund's adjuvant
(CFA) (Chondrex, Bellevue WA) and supplemented with 400 μg/ml of
M. tuberculosis (Difco Laboratories, Sparks MD). Additionally, mice
were injected intravenously on days 0 and 2 with 200 ng of pertussistoxin (Sigma-Aldrich, St. Louis MI). The animals were scored daily for
clinical signs of EAE on a 5-point scale: 0=no disease; 1=decreased
tail tone; 2=hind-limb weakness or partial paralysis; 3=complete
hind-limb paralysis; 4=front and hind limb paralysis.
2.4. Serology
For the analysis of MOG-speciﬁc autoantibodies, we collected plas-
ma from mice in homeostatic conditions or after immunization with
MOG protein. IgG antibodies speciﬁc for MOG were determined
using the Anti-MOG (1-125aa) IgG ELISA Kit (AnaSpec) following
the manufacturer's recommendations.
2.5. Flow cytometric detection of surface proteins
Spleens were collected from non-immunized mice and from animals
immunized with MOG. Single-cell suspensions were obtained, erythro-
cytes removed, and cells were stained at 4 °C with the indicated
ﬂuorochrome-conjugated anti-mouse monoclonal antibodies for surface
markers or with isotype- and concentration-matched control antibodies.
Antibodies used in this study included Alexa700-conjugated anti-CD3,
Alexa700-conjugated anti-CD4, phycoerythrin (PE)-Cy7-conjugated
anti-CD4, Alexa 780-conjugated anti-CD8, PE-conjugated anti-
vβ11, FITC-conjugated anti-CD44 and APC-conjugated anti-CD62L
(all eBioscience, San Diego, CA). Flow cytometric analysis was
performed and analyzed using a 7-color FACS Canto (BD Biosciences,
San Jose CA) and FlowJo software (Tree Star Inc., Ashland OR). The
results are expressed as percentage of positive cells.
2.6. Analysis of T cell survival
To assess apoptosis and survival capacity, splenic T cells were
recovered and stimulated for 72 h in vitro with MOG protein or
anti-CD3/CD28 antibodies. Staining with 7-aminoactiomycin D
(BD Biosciences) and APC-conjugated Annexin-V were used to
quantify apoptotic and necrotic cells. The results are expressed as
percentage of positive cells.
2.7. Analysis of T cell cytokine production
Splenic T cells were cultured in RPMI supplemented with 10% FCS,
β-mercaptoethanol, L-glutamine, gentamicin sulfate and penicillin/
streptomycin, and stimulated in 96-well plates for 6 h with phorbol
myristate acetate (PMA, 10 ng/ml; Sigma-Aldrich) and ionomycin
(1 μM; Sigma-Aldrich). Alternatively, cells were stimulated with
MOG protein (0.6, 1.6, 3 or 15 μg/ml; AnaSpec, Freemont, USA) or
anti-CD3 (1 μg/ml) and anti-CD28 antibodies (1 μg/ml) (both kindly
provided by Dr. L. Boon, Bioceros BV, Utrecht, NL) for 48 h. For the
detection of intracellular cytokines, Brefeldin A (5 μg/ml; Sigma-
Aldrich) was added for the last 4 h of culture, and cells were ﬁxed
and permeabilized using an intracellular staining kit (BD BioSci-
ences). Cells were stained with Alexa 488-conjugated anti-IL-17,
PerCP-Cy5.5-conjugated anti-IFNγ, PE-Cy7-conjugated anti-IL-2, and
APC-conjugated anti-TNFα (eBiosciences).
2.8. Flow cytometric detection of FoxP3+ T cells
To quantify the percentage of FoxP3+ cells, splenic lymphocytes
were recovered, ﬁxed and permeabilized with the FoxP3+ Transcrip-
tion Factor Staining Buffer Set (eBiosciences), and stained at 4 °C with
the indicated ﬂuorochrome-conjugated anti-mouse monoclonal
antibodies or with isotype- and concentration-matched control
antibodies: Alexa700-conjugated anti-CD3, phycoerythrin (PE)-
Cy7-conjugated anti-CD4, Alexa 780-conjugated anti-CD8, PE-
conjugated anti-vβ11 and APC-conjugated anti-FoxP3 (eBioscience).
To assess the effect of CD70 overexpression on FoxP3 positive T cells
Fig. 1. EAE development in 2D2xCD70 mice. 2D2xCD70 and 2D2mice were observed from 6 to 20 weeks of age to record the development of spontaneous EAE. Neurological signs of
disease were scored daily. At the end of the experiment, the incidence (A) and the severity (B) of spontaneous EAE were compared between groups. In a second experiment,
2D2xCD70 and 2D2 mice were immunized with a low dose of recombinant MOG protein. The development of EAE was monitored for 10 days and the neurological signs of disease
were scored daily. The incidence (C) and the severity (D) of EAE were compared between groups.
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suspensions using anti-CD4 and anti-CD19 antibodies conjugated tomag-
netic beads andMS columns (Miltenyi BiotecGmbH, BergischGladbach,
Germany). Cocultures of 5×106 T and 5×106 B cells/ml were set up in
RPMI supplemented with 10% FCS, β-mercaptoethanol, L-glutamine,
gentamicin sulfate and penicillin/streptomycin. Cells were cultured in
96-well plates with medium alone or medium supplemented with MOG
peptide (1, 3 or 10 μg/ml; GenScript, Piscataway, NJ) or anti-CD3
(1 μg/ml) and anti-CD28 antibodies (1 μg/ml) (both provided by
Dr. L. Boon, Bioceros BV, Utrecht, NL). Cells were recovered after
72 h and stained as indicated previously.
2.9. Statistics
Gehan–Breslow–Wilcoxon test was used to compare the incidence
of EAE between groups of mice. Flow cytometric data were compared
using Mann–Whitney non-parametrical t-test. P-values ≤0.05 were
considered statistically signiﬁcant.
3. Results
3.1. B cell-speciﬁc CD70 overexpression increased the susceptibility to
EAE
Non-immunized 2D2 single transgenic mice and 2D2xCD70 mice
were monitored daily for the development of spontaneous EAE upto 20 weeks of age. In line with published data (Bettelli et al.,
2003), only 1/32 (3%) 2D2 mice developed signs of neurological
disease, starting at week 10 and reaching a maximal EAE score of 2.
In contrast, 20% of the 2D2xCD70 mice (9/44, p=0.03) developed
spontaneous EAE (Fig. 1A). The median disease onset was 12 weeks
(range: 5–17), the median maximum score was 3 (range: 1–4), and
the signs of disease followed the classical pattern of progressive
paralysis from tail to hind limbs to front limbs. The severity of EAE,
estimated by comparing the area under the curve of clinical scores
in time per group, was also signiﬁcantly higher in the 2D2xCD70
mice than in the 2D2 mice (p=0.03, Fig. 1B).
To study whether the constitutive expression of CD70 on B cells
also enhanced the development of autoimmune disease after MOG
immunization, 2D2 and 2D2xCD70 animals were injected with a
low dose of recombinant MOG protein in CFA. As CD70 transgenic
mice are characterized by a profound B cell depletion, we immunized
the mice between week 7 and 8 of age because the number of B cells
was still comparable between 2D2 and 2D2xCD70 mice at that age
(data not shown). Clinical monitoring during 10 days indicated that
upon immunization, EAE developed in 31% (5/16) of the single
transgenic 2D2 mice versus 72% (13/18) of the 2D2xCD70 animals
(p=0.012) (Fig. 1C). Signs of disease appeared in both groups
around the same time (2D2: median day 9 (range: 6–9 days) versus
2D2xCD70: median day 8 (range: 8–9 days)). Nonetheless, the
severity of EAE indicated by the area under the curve of the clinical
scores of all animals per group, was signiﬁcantly higher in the
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disease over a longer time period as it is known that mice of the 2D2
background develop EAE of great severity upon immunization
(Bettelli et al., 2003). However, the data of these two experiments
demonstrated that CD70 overexpression on B cells is sufﬁcient to
promote progression towards full-blown autoimmune disease in
MOG-speciﬁc TCR transgenic animals.
3.2. CD70 overexpression did not alter the B cell compartment in EAE
As CD70 ligation can inﬂuence B cell proliferation and activation
by reverse signaling (Arens et al., 2004a), but also induces B cellFig. 2. Effect of CD70 costimulation on B cells. Blood was collected from 2D2xCD70 and 2D2
centage of CD19+ B cells was determined by ﬂow cytometry. 2D2xCD70 and 2D2 littermates
of CD19+ (C) and CD5+ regulatory B cells (D) in the spleen were determined by ﬂow cytom
staining after ex-vivo re-stimulation. Serum was collected from non immunized 2D2xCD70depletion due to the formation of IFNγ producing T cells (Arens et
al., 2001), we investigated whether the increased EAE susceptibility
of the 2D2xCD70 animals was associated with alterations in the B
cell compartment. Non-immunized 2D2 and 2D2xCD70 mice showed
comparable numbers of splenic B cells at week 7, but analysis at later
time points indicated a progressive and signiﬁcant drop in B cell
numbers in 2D2xCD70 mice (p=0.004 at week 9 and p=0.009 at
week 12) (Fig. 2A and B), suggesting that also in this model chronic
costimulation through CD70 leads to B cell depletion over time
(Arens et al., 2001). Immunization with MOG protein at week 7 did
not inﬂuence B cell numbers as ﬂow cytometric analysis 10 days
after immunization showed similar percentages of CD19+ cells inmice in homeostatic conditions at 9 weeks (A) and 12 weeks (B) of age and the per-
were immunized with a low dose of MOG protein. At the peak of disease the frequency
etry. The percentage of TNF producing B cells (E) was also determined by intracellular
and 2D2 mice and the titers of anti-MOG autoantibodies were determined by ELISA (F).
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(28% (23–29) versus 28% (23–34)) (Fig. 2C). Further phenotypic
and functional analysis of the splenic B cell population in immunized
mice revealed similar numbers of CD19+ B cells with the CD5+
regulatory phenotype (12% (10–14) in 2D2 versus 10% (8–12) in
2D2xCD70) (Fig. 2D). Upon ex vivo stimulation with PMA/Ionomycin/
LPS, a similar number of IL-10 producing CD5+ CD19+ B cells (data
not shown) and a tendency towards decreased TNF expression by B
cells in 2D2xCD70 mice (6% (5–7)) versus 2D2 littermates (8% (6–9);
p=0.054) were observed (Fig. 2E). As to the potential impact of consti-
tutive CD70 costimulation on autoantibodies, ELISA measurement of
serum anti-MOG antibody levels at week 20 in non immunized mice
actually revealed decreased titers in 2D2xCD70 mice (median OD:
0.08 (0.03-0.13)) versus 2D2 mice (median OD: 0.20, (0.16-0.23))
(Fig. 2F). This observation was consistent with the phenotype of the
CD70 single transgenic mice which show ablation of IgG antibodies
(Arens et al., 2001). Taken together, alterations in B cell numbers and
function did not explain the increased susceptibility of 2D2xCD70
mice to EAE as the decreases in B cells and autoantibodies are more
compatible with protection against disease progression (Ruddle et al.,
1990; Ait-Oufella et al., 2010).
3.3. CD70 overexpression by B cells increased the number of autoreactive
T cells
Constitutive CD70 expression by B cells in TCR wild type mice
leads to a signiﬁcant expansion of effector CD4 and CD8 T cells
through increased survival (Arens et al., 2001; Hendriks et al., 2003;Fig. 3. Effect of CD70 costimulation on the size of the T cell compartment. 2D2xCD70 and 2D
(A) and vβ11+ CD4+ T cells (B) in the spleen were determined by ﬂow cytometry 10 day
cells (D) was determined in peripheral blood of 2D2xCD70 and 2D2 mice in homeostatic cvan Gisbergen et al., 2011). A similar effect was observed in the 2D2
background as MOG-immunized animals displayed a similar overall
splenic cellularity but an increase of the CD4+ T cells in 2D2xCD70
mice (28% (26–31)) versus 2D2 littermate controls (22% (18–27);
p=0.03) (Fig. 3A). Additional characterization showed that vβ11+
CD4+ T lymphocytes, which bear the MOG-speciﬁc TCR, represented
25% (23–29) of the total lymphocyte pool in 2D2xCD70 mice versus
20% (16–25) in 2D2 single transgenic animals immunized with
MOG protein (p=0.028) (Fig. 3B). Analysis of non immunized
animals at week 12 did not reveal a similar expansion of CD4+ T
cells (28 versus 32%) (Fig. 3C) or vβ11+ CD4+ T cells (27 versus
31% at week 12) (Fig. 3D) in 2D2xCD70 versus 2D2 mice, thus
conﬁrming that this expansion was driven by the immunization
with the autoantigen.
To assess whether the expansion of the autoreactive CD4+ T cell
pool in 2D2xCD70 mice was related to enhanced T cell survival
upon antigenic stimulation, we collected splenocytes from mice
immunized in vivo with MOG, restimulated them in vitro with the
same antigen and measured T cell survival by 7-AAD staining.
CD4+ T cells of 2D2xCD70 mice showed a signiﬁcant albeit small
survival advantage in comparison with 2D2 mice (p=0.04 after
restimulation with 1.6 μg MOG/ml, p=0.04 with 5 μg MOG/ ml;
p=0.03 with 15 μg MOG/ml). This difference was not observed
upon non-speciﬁc stimulation with anti-CD3/CD28 and upon MOG
stimulation of splenocytes obtained from non immunized animals
(data not shown). The frequency of CD8+ T cells, which is very
small in the 2D2 genetic background, was not different between
2D2 and 2D2xCD70 mice (data not shown). Taken together, these2 littermates were immunized with a low dose of MOG protein. The frequency of CD4+
s after immunization. As comparison, the frequency of CD4+ (C) and vβ11+ CD4+ T
onditions at 12 weeks of age.
Fig. 4. Effect of CD70 costimulation on the effector proﬁle of T cells. 2D2xCD70 and 2D2
littermates were immunized with a low dose of MOG protein. The frequencies of
CD44+ CD62L− (A), CD44+ CD62L+ (B) and CD44-CD62L− (C) vβ11+ CD4+ T
cells in the spleen were determined by ﬂow cytometry 10 days after immunization.
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creases the size of the autoreactive T cell pool in the 2D2xCD70
mice, probably as a result of increased survival after in vivo priming.
3.4. Constitutive CD70 expression by B cells did not alter the effector
proﬁle of autoreactive T cells
We next assessed whether the increase of autoreactive T cells
upon MOG immunization in 2D2xCD70 mice was associated with an
altered effector proﬁle. Analysis of splenic vβ11+ autoreactive T
cells, however, did not show a shift towards CD44+ CD62L− effector
cells in immunized 2D2xCD70 (10% (6–11)) versus 2D2 mice (8%
(6–10)) (Fig. 4A). Similarly, no differences were observed in the
CD44+ CD62L+ central memory and the CD44-CD62L+ naïve
subsets (Fig. 4B and C).
As both Th1 and Th17 cells play a pathogenic role in EAE (Jager et
al., 2009; El-behi et al., 2010), we next assessed whether B cell specif-
ic CD70 overexpression had a qualitative rather than quantitative
effect on effector T cells. In vitro PMA/ionomycine restimulation of
splenocytes recovered after in vivo immunization with MOG revealed
equivalent expression of IFNγ (12% (8–16) versus 12% (10–15))
(Fig. 5A), IL-17 (6% (3–7) versus 5% (4–7)) (Fig. 5B), and IL-2 (16%
(11–18) versus 13% (11–16)) (Fig. 5C) by CD4+ T lymphocytes in
2D2 versus 2D2xCD70 mice. However, 2D2xCD70 splenocytes
contained fewer TNFα producing CD4 T cells than the 2D2 controls
(42% (34–44) versus 50% (45–53); p=0.02) (Fig. 5D). Consistent
with these data on PMA/Ionomycin stimulation, in vitro restimulation
with 0.6 μg/ml and 1.6 μg/ml of MOG led to a signiﬁcant lower
number of TNFα expressing autoreactive T cells in 2D2xCD70 versus
2D2 mice (p=0.01 and p=0.03, respectively), but this difference
disappeared at higher doses (Fig. 5D). In summary, these data
indicate that constitutive CD70 overexpression by B cells did not
alter the effector proﬁle of autoreactive T cells in this model with
the exception of slightly decreased TNFα production.
3.5. The constitutive expression of CD70 on B cells decreased the frequency
of FoxP3+ T cells
As we did not observe a clear qualitative shift in the autoimmune
effector T cells, we ﬁnally assessed whether constitutive CD70 expres-
sion by B cells might have affected the size of the regulatory T cell
pool in vivo. We collected splenocytes of the 2D2 and 2D2xCD70
animals immunized with MOG protein and analyzed the expression
of the transcription factor FoxP3 by CD4+ speciﬁc T lymphocytes.
The percentage of vβ11+ CD4+ T cells positive for FoxP3 was signif-
icantly reduced in the 2D2xCD70 mice (3% (3–5)) versus the 2D2
littermate controls (6% (5–7); p=0.04) (Fig. 6A). A similar reduction
in FoxP3 positive T cells was also observed in the vβ11− CD4+ T cell
subset (7% (5–8) in 2D2xCD70 versus 10% (8–15) in 2D2; pb0.001)
(Fig. 6B). To establish whether overexpression of CD70 by B cells
also affected the generation of FoxP3+ regulatory T cells in vitro,
we cultured naïve 2D2 T cells with CD70 expressing B cells in vitro
for 72 h in the presence of MOG and TGFβ and measured the differen-
tiation of T lymphocytes into CD4+ FoxP3+ T cells. For all the doses
of MOG peptide tested, the frequency of FoxP3 expressing T cells was
signiﬁcantly decreased when CD70+ B cells were used as antigen
presenting cells in comparison with wild type B cells (Fig. 6C). In
conjunction with the ex vivo data, our results illustrate that
CD70-mediated costimulation provided by B cells is sufﬁcient to
impair the formation of antigen-speciﬁc FoxP3+ CD4+ regulatory
T cells, possibly enhancing the susceptibility to autoimmunity.
4. Discussion
The development of an adequate T cell response is a multi-step
process requiring not only recognition of the antigen by the T cellreceptor (signal 1) but also appropriate costimulation (signal 2)
and instructive signals by cytokines (signal 3) to allow for prolifera-
tion, survival, and differentiation into speciﬁc effector cells. Over the
last years, extensive work on CD70-CD27 has established that this
costimulation pair plays an important role in determining the
outcome of T cell responses (Nolte et al., 2009). CD70, which is
transiently expressed on activated lymphocytes and dendritic cells,
can engage CD27 on naïve and recently activated CD4+ and CD8+
T cells and thereby contribute to the formation of the effector pool
by inducing proliferation and survival. Using a model of constitutive
CD70 expression by B cells, we previously demonstrated that chronic
costimulation through CD70 can cause immunopathology by
exhausting the T cell and B cell pools (Arens et al., 2001; Tesselaar
et al., 2003). The impact of CD70 stimulation in autoimmune disease
though, has not been thoroughly explored. In contrast to overexpression
of other costimulatory molecules such as OX40L(Murata et al., 2002)
Fig. 5. Effect of CD70 costimulation on the cytokine proﬁle of T cells Splenocytes from immunized mice were re-stimulated ex-vivo with PMA-Ionomycin and the percentages of
IFNγ (A), IL-17 (B), IL-2 (C) and TNFα (D) producing cells were determined by ﬂow cytometry. Splenocytes from immunized mice were also cultured with medium alone, MOG
protein or anti-CD3/anti-CD28 antibodies. The percentages of TNFα (E) producing cells were determined by ﬂow cytometry.
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by B cells did not develop spontaneously autoimmune phenomena.
However, these data remain difﬁcult to interpret as B cells, which play a
crucial role in many autoimmune diseases, are rapidly and profoundly
depleted in an IFNγ dependent way by activated T cells in these mice
(Arens et al., 2001). This depletion also precludes the study of classical
autoimmune models such as collagen-induced arthritis and MOG-
induced experimental autoimmune encephalomyelitis as B cells are
crucial to the pathogenesis of these diseases (Lyons et al., 1999; Brand
et al., 2003; Cho et al., 2007; Carter et al., 2012).
Here, we circumvented this issue by using 2D2 TCR transgenic
animals with speciﬁcity to MOG. These mice display clear subclinical
autoimmunity but only rarely progress spontaneously to overtautoimmune disease (Bettelli et al., 2003). B cell depletion in
CD70TG mice is dependent on TCR-triggering (Tesselaar et al.,
2003). As in the 2D2 animals the majority of the peripheral T cells
are speciﬁc for MOG, an autoantigen sequestered in the central
nervous system, we hypothesized that unless autoimmune disease
was triggered, only few (non-MOG speciﬁc) T cells would be activat-
ed by the CD70 overexpression and thus IFNγ dependent B cell deple-
tion would be delayed and mild in the 2D2xCD70 mice versus the
CD70 mice. In agreement with this hypothesis, we observed normal
numbers of B cells at week 7 and progressive but incomplete B cell
depletion at week 9 and 12. Hence, the 2D2 TCR transgenic mouse
provides a unique opportunity to study the effect of constitutive
CD70 costimulation by B cells on autoimmunity in general and on
Fig. 6. Effect of CD70 costimulation on the regulatory T cell compartment. 2D2xCD70
and 2D2 littermates were immunized with a low dose of MOG protein. The frequencies
of FoxP3+ vβ11+ (A) and FoxP3+ vβ11− CD4+ T cells in the spleen were deter-
mined by ﬂow cytometry 10 days after immunization. CD4+ T lymphocytes from
non immunized 2D2 mice were cultured with CD70+ or wild type B lymphocytes in
medium alone, anti-CD3/anti-CD28 antibodies or different doses of MOG peptide. The
percentages of FoxP3+ vβ11+ CD4+ T cells were determined by ﬂow cytometry (C).
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particular. Moreover, autoreactive T cells can be easily tracked in
these animals by the use of the vβ11 TCR chain; and we and others
previously demonstrated that, when EAE develops in them, B cells
play an important role as antigen-presenting cells (Bettelli et al.,
2006; Krishnamoorthy et al., 2006).Two types of experiments conﬁrmed our hypothesis that CD70
costimulation can trigger and/or accelerate autoimmune disease.
Firstly, 20% of the 2D2 mice overexpressing CD70 spontaneously
developed EAE without MOG immunization. To extend this observa-
tion, we immunized 7 weeks old mice with MOG and observed a
similar increase in incidence and severity of EAE in the presence of
constitutive CD70 costimulation. We used low dosages of MOG in
these experiments as 2D2 mice develop very severe EAE upon full
immunization, even in the absence of CD70 costimulation (Bettelli
et al., 2003). These data are in agreement with studies showing
that blocking anti-CD70 antibodies can prevent PLP-induced EAE
(Nakajima et al., 2000) and suppress Theiler's murine encephalomy-
elitis virus-induced demyelinating disease (Yanagisawa et al., 2010).
Taken together, these data consistently indicate that CD70-mediated
costimulation plays an important role in the development of T
cell-dependent CNS autoimmunity.
Further analysis conﬁrmed that the mechanisms of increased
autoimmunity in the presence of constitutive CD70 expression are
related to T cell rather than B cell alterations. Indeed, the number,
phenotype and cytokine production of B cells was not altered upon
MOG immunization in CD70 versus WT animals. Moreover, we did
not observe an increase of anti-MOG antibodies in the diseases
2D2xCD70 animals versus the 2D2 littermates. In contrast with the
B cell compartment, analysis of the T cells indicated two major alter-
ations. Firstly, we observed an expansion of the autoreactive vβ11+
CD4+ T cell pool in the 2D2xCD70 mice. This expansion is triggered
by antigen-exposure, as it was not observed in 12 weeks-old
non-immunized animals. In vitro analysis suggested that this accu-
mulation is most likely due to enhanced survival of the autoreactive
T cells. However, in contrast with previous reports under homeostatic
conditions as well as in tumour and viral infection models (Arens et
al., 2004b), this expansion was not associated with a shift towards
effector-memory T cells. Functional analysis of the autoreactive T
cells did not show an increase of Th1 or Th17 responses and even a
moderate impairment of TNFα production. This suggests that the
timing and tuning of the CD70-CD27 costimulation may be different
in this autoimmune model versus the previously studied models
and/or that the TCR transgenic T cells are less susceptible to these
effects. Alternatively, the autoreactive T cells triggered by CD70 and
MOG to develop into Th1 skewed effector cells migrate rapidly from
the periphery to the CNS and can therefore not be detected in the
lymphoid tissues in this model.
The second major alteration in the T cell pool was the decrease in
vivo and in vitro in FoxP3+ regulatory T cells. Previous analysis did
not show an impact of CD70 overexpression on the frequency and/
or activation status of T regs under homeostatic conditions (Libregts
et al., 2011), but the inﬂuence of CD70 over the course of an immune
reaction may be different. Interestingly, recent studies using CD70-
expressing B cells from non-Hodgkin's lymphomas and chronic
lymphocytic leukemia (Yang et al., 2007; Jak et al., 2009) indicated
that CD70 can induce FoxP3 expression and thereby enhance
formation and survival of Tregs. The CD27/CD70 pathway has also
been shown to be essential for the generation of regulatory cells
after intratracheal delivery of alloantigens (Aramaki et al., 2003).
Although we observe the opposite effect in our autoimmune model,
which may again be related to the timing and tuning of CD70
costimulation during the immune response as well as the availability
of the antigen, the concept of regulation of regulatory T cells by
costimulatory molecules is not novel. Indeed, GITR-GITRL interactions
were shown to promote expansion of both effector and regulatory T
cells (van Olffen et al., 2009) whereas OX40/OX40L costimulation
affects the induction of T regs by expanding the memory T cell pool
(Xiao et al., 2008). Similarly, signalling of B7 molecules through CD28
and CTLA4 has been shown to affect the regulatory T cell pool
(Salomon et al., 2000; Tang et al., 2003), with important functional
consequences in vivo (Poirier et al., 2010). Our data thus indicate that
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autoreactive effector and regulatory T cells in autoimmunity and this
shift in the balance may explain the increased incidence and severity
of EAE in 2D2xCD70 transgenic mice.
The fact that enhanced expression of CD70 by B cells triggers EAE in
this model provides further support for the concept that B lymphocytes
may promote autoimmune disease through a variety of mechanisms.
Besides terminal differentiation towards autoantibody-producing plas-
ma cells, B cells appear to be potent antigen presenting cells able to
steer autoreactive T cell responses. Their role in T cell activation appears
not only to be determined by their BCR-related ability to capture and
process autoantigens with high efﬁcacy but also by their expression of
costimulatory molecules. The transgenic overexpression model used
in the present study may mimic to a certain extend the unchecked
CD70 expression in humans during chronic viral infections and autoim-
mune diseases such as rheumatoid arthritis and systemic lupus
erythematosus (Wolthers et al., 1996; Oelke et al., 2004; Lee et al.,
2007), or the CD70-CD27 interactions evidenced in rheumatoid arthritis
(Tak et al., 1996). Strikingly, diseases such as RA and MS might be
triggered by viral infections, including EBV infection of B cells
(Franssila and Hedman, 2006; Sawada et al., 2007; Toussirot and
Roudier, 2007; Franciotta et al., 2008; Pender, 2009, 2011), and show
a profound clinical response to B cell depletion by anti-CD20 (Dorner
et al., 2010; Townsend et al., 2010). Whether abnormal expression of
CD70 by chronically activated B cells contributes directly to the patho-
genesis of these diseases remains to be further investigated. Neverthe-
less, this study highlights the fact that, besides CTLA-4, the blockade of
other costimulatory pairs such as CD70-CD27, may hold therapeutic
potential in the treatment of MS and other autoimmune diseases.
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